📣 VC round data is live. Check it out!
- Public Comps
- Synmosa Biopharma
Synmosa Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Synmosa Biopharma and similar public comparables like Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare and more.
Synmosa Biopharma Overview
About Synmosa Biopharma
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.
Founded
1970
HQ

Employees
473
Website
Financials (FY)
EV
$471M
Valuation Multiples
Start free trialSynmosa Biopharma Financials
Synmosa Biopharma reported last fiscal year revenue of $197M and EBITDA of $38M.
In the same fiscal year, Synmosa Biopharma generated $85M in gross profit, $38M in EBITDA, and $26M in net income.
Synmosa Biopharma P&L
In the most recent fiscal year, Synmosa Biopharma reported revenue of $197M and EBITDA of $38M.
Synmosa Biopharma is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 19%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Synmosa Biopharma Stock Performance
Synmosa Biopharma has current market cap of $484M, and enterprise value of $471M.
Market Cap Evolution
Synmosa Biopharma's stock price is $0.96.
Synmosa Biopharma share price decreased by 0.2% in the last 30 days, and by 8.2% in the last year.
Synmosa Biopharma has an EPS (earnings per share) of $0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $471M | $484M | -0.2% | -0.2% | -2.0% | -8.2% | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynmosa Biopharma Valuation Multiples
Synmosa Biopharma trades at 2.4x EV/Revenue multiple, and 12.3x EV/EBITDA.
Synmosa Biopharma Financial Valuation Multiples
As of June 2, 2026, Synmosa Biopharma has market cap of $484M and EV of $471M.
Synmosa Biopharma has a P/E ratio of 18.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Synmosa Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Synmosa Biopharma Margins & Growth Rates
In the most recent fiscal year, Synmosa Biopharma reported gross margin of 43%, EBITDA margin of 19%, and net margin of 13%.
Synmosa Biopharma Margins
Synmosa Biopharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Synmosa Biopharma Operational KPIs
Synmosa Biopharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Synmosa Biopharma Competitors
Synmosa Biopharma competitors include Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare, Luzhu Biotech, Ovid Therapeutics, Contineum Therapeutics, Autolus Therapeutics, CHO Pharma and CytoDyn.
Most Synmosa Biopharma public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3164.6x | 5472.1x | (14.4x) | (14.2x) | |||
| 8.5x | 10.1x | (3.0x) | - | |||
| 22.2x | 19.1x | (111.9x) | 698.3x | |||
| 1.6x | - | 15.2x | - | |||
| - | 11.5x | (21.8x) | (1644.4x) | |||
| 46.1x | 78.3x | (7.9x) | - | |||
| - | 87.2x | (3.7x) | (3.4x) | |||
| 4.5x | 3.5x | (1.4x) | (1.4x) | |||
This data is available for Pro users. Sign up to see all Synmosa Biopharma competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Synmosa Biopharma
| When was Synmosa Biopharma founded? | Synmosa Biopharma was founded in 1970. |
| Where is Synmosa Biopharma headquartered? | Synmosa Biopharma is headquartered in Taiwan. |
| How many employees does Synmosa Biopharma have? | As of today, Synmosa Biopharma has over 473 employees. |
| Is Synmosa Biopharma publicly listed? | Yes, Synmosa Biopharma is a public company listed on Taipei Exchange. |
| What is the stock symbol of Synmosa Biopharma? | Synmosa Biopharma trades under 4114 ticker. |
| When did Synmosa Biopharma go public? | Synmosa Biopharma went public in 2003. |
| Who are competitors of Synmosa Biopharma? | Synmosa Biopharma main competitors include Avacta Group, C4 Therapeutics, Medigen Vaccine Biologics, PKU Healthcare, Luzhu Biotech, Ovid Therapeutics, Contineum Therapeutics, Autolus Therapeutics, CHO Pharma, CytoDyn. |
| What is the current market cap of Synmosa Biopharma? | Synmosa Biopharma's current market cap is $484M. |
| What is the current revenue of Synmosa Biopharma? | Synmosa Biopharma's last fiscal year revenue is $197M. |
| What is the current EV/Revenue multiple of Synmosa Biopharma? | Current revenue multiple of Synmosa Biopharma is 2.4x. |
| Is Synmosa Biopharma profitable? | No, Synmosa Biopharma is not profitable. |
| How many companies Synmosa Biopharma has acquired to date? | Synmosa Biopharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Synmosa Biopharma has invested to date? | Synmosa Biopharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Synmosa Biopharma
Lists including Synmosa Biopharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.